Wells Fargo & Company Jounce Therapeutics, Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.9 - $1.85 $6,719 - $13,812	7,466 Added 2347.8%	7,784 $14,000
Q4 2022 Feb 13, 2023	SELL	$0.64 - $1.99 $53 - $167	-84 Reduced 20.9%	318 $0
Q3 2022 Nov 14, 2022	SELL	$2.73 - $4.92 $1,070 - $1,928	-392 Reduced 49.37%	402 $1,000
Q2 2022 Aug 12, 2022	SELL	$2.8 - $7.67 $161,565 - $442,574	-57,702 Reduced 98.64%	794 $2,000
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $54,083 - $76,851	-8,999 Reduced 13.33%	58,496 $397,000
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $883,282 - $1.2 Million	-124,231 Reduced 64.8%	67,495 $564,000
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $235,947 - $408,694	46,815 Added 32.31%	191,726 $1.42 Million
Q2 2021 Aug 16, 2021	SELL	$6.58 - $10.66 $645,122 - $1.05 Million	-98,043 Reduced 40.35%	144,911 $985,000
Q1 2021 May 13, 2021	BUY	$6.73 - $13.87 $877,363 - $1.81 Million	130,366 Added 115.79%	242,954 $2.5 Million
Q4 2020 Feb 09, 2021	BUY	$6.37 - $10.33 $128,916 - $209,058	20,238 Added 21.91%	112,588 $788,000
Q3 2020 Nov 05, 2020	BUY	$4.58 - $10.95 $40,807 - $97,564	8,910 Added 10.68%	92,350 $753,000
Q2 2020 Aug 13, 2020	BUY	$4.17 - $7.58 $39,235 - $71,320	9,409 Added 12.71%	83,440 $576,000
Q1 2020 May 14, 2020	BUY	$2.91 - $8.7 $215,430 - $644,069	74,031 New	74,031 $351,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.